CTLA4 and neoplasm: The circulating adoptive CD8+ T cells activated by this treatment possess a high tumor-targeting ability to gather into the tumor site, thereby boosting tumor cell apoptosis and pro-inflammatory reaction, Therefore, anti-CTLA-4 Nb-modified liposomes-mediated CTLA-4 blockade has great potential for clinical application by acting as a novel strategy for interrupting T cell depletion from immune checkpoints that can be easily used for adoptive therapy in activated T cells.